These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 24308713

  • 1. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen.
    Brooke JS.
    Expert Rev Anti Infect Ther; 2014 Jan; 12(1):1-4. PubMed ID: 24308713
    [Abstract] [Full Text] [Related]

  • 2. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment.
    Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ.
    Expert Rev Anti Infect Ther; 2011 Apr; 9(4):471-88. PubMed ID: 21504403
    [Abstract] [Full Text] [Related]

  • 3. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.
    Brooke JS.
    Clin Microbiol Rev; 2012 Jan; 25(1):2-41. PubMed ID: 22232370
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial susceptibility pattern of Burkholderia cepacia complex & Stenotrophomonas maltophilia over six years (2007-2012).
    Gautam V, Kumar S, Kaur P, Deepak T, Singhal L, Tewari R, Ray P.
    Indian J Med Res; 2015 Oct; 142(4):492-4. PubMed ID: 26609043
    [No Abstract] [Full Text] [Related]

  • 5. Community-acquired infection due to Stenotrophomonas maltophilia: a rare cause of septic arthritis.
    Aydemir C, Aktaş E, Eldeş N, Kutsal E, Demirel F, Ege A.
    Turk J Pediatr; 2008 Oct; 50(1):89-90. PubMed ID: 18365601
    [Abstract] [Full Text] [Related]

  • 6. Stenotrophomonas maltophilia: An emerging opportunistic nosocomial pathogen in a tertiary care hospital in Al Batinah North Governorate, Oman.
    Sannathimmappa MB, Nambiar V, Aravindakshan R, Al-Kasaby NM.
    Sultan Qaboos Univ Med J; 2021 Feb; 21(1):e66-e71. PubMed ID: 33777425
    [Abstract] [Full Text] [Related]

  • 7. Clinical importance of Stenotrophomonas maltophilia nosocomial pneumonia due to its high mortality in hemodialysis patients.
    Wakino S, Imai E, Yoshioka K, Kamayachi T, Minakuchi H, Hayashi K, Inamoto H, Itoh H.
    Ther Apher Dial; 2009 Jun; 13(3):193-8. PubMed ID: 19527465
    [Abstract] [Full Text] [Related]

  • 8. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen.
    Senol E.
    J Hosp Infect; 2004 May; 57(1):1-7. PubMed ID: 15142709
    [Abstract] [Full Text] [Related]

  • 9. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.
    Lobo LJ, Tulu Z, Aris RM, Noone PG.
    Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407
    [Abstract] [Full Text] [Related]

  • 10. Stenotrophomonas maltophilia drug resistance.
    Sanchez MB, Hernandez A, Martinez JL.
    Future Microbiol; 2009 Aug; 4(6):655-60. PubMed ID: 19659422
    [Abstract] [Full Text] [Related]

  • 11. [Necrotizing otitis externa caused by Stenotrophomonas maltophilia].
    Börner D, Marsch WC, Fischer M.
    Hautarzt; 2003 Nov; 54(11):1080-2. PubMed ID: 14593466
    [Abstract] [Full Text] [Related]

  • 12. [Stenotrophomonas maltophilia and tigecycline in clinical practice].
    Conde-Estévez D, Grau S, Alvarez-Lerma F.
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):170-1. PubMed ID: 22277371
    [No Abstract] [Full Text] [Related]

  • 13. Risk factors for levofloxacin resistance in Stenotrophomonas maltophilia from respiratory tract in a regional hospital.
    Pien CJ, Kuo HY, Chang SW, Chen PR, Yeh HW, Liu CC, Liou ML.
    J Microbiol Immunol Infect; 2015 Jun; 48(3):291-5. PubMed ID: 24239064
    [Abstract] [Full Text] [Related]

  • 14. Stenotrophomonas maltophilia: an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host.
    Baumrin E, Piette EW, Micheletti RG.
    BMJ Case Rep; 2017 Dec 20; 2017():. PubMed ID: 29269358
    [Abstract] [Full Text] [Related]

  • 15. Extended multidrug-resistant Stenotrophomonas maltophilia septicemia in a severely burnt patient.
    Leung C, Drew P, Azzopardi EA.
    J Burn Care Res; 2010 Dec 20; 31(6):966. PubMed ID: 20852428
    [No Abstract] [Full Text] [Related]

  • 16. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer.
    Safdar A, Rolston KV.
    Clin Infect Dis; 2007 Dec 15; 45(12):1602-9. PubMed ID: 18190323
    [Abstract] [Full Text] [Related]

  • 17. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan.
    Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC, TSAR Hospitals.
    J Microbiol Immunol Infect; 2012 Apr 15; 45(2):120-6. PubMed ID: 22154599
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge.
    Gil-Gil T, Martínez JL, Blanco P.
    Expert Rev Anti Infect Ther; 2020 Apr 15; 18(4):335-347. PubMed ID: 32052662
    [Abstract] [Full Text] [Related]

  • 19. Stenotrophomonas maltophilia: an emerging opportunist human pathogen.
    Looney WJ, Narita M, Mühlemann K.
    Lancet Infect Dis; 2009 May 15; 9(5):312-23. PubMed ID: 19393961
    [Abstract] [Full Text] [Related]

  • 20. Optimizing therapy for Stenotrophomonas maltophilia.
    Muder RR.
    Semin Respir Crit Care Med; 2007 Dec 15; 28(6):672-7. PubMed ID: 18095231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.